Financial Analysis: Boston Scientific Corporation (BSX) & Mazor Robotics (NASDAQ:MZOR)
Boston Scientific Corporation (NYSE: BSX) and Mazor Robotics (NASDAQ:MZOR) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations and dividends.
Valuation and Earnings
This table compares Boston Scientific Corporation and Mazor Robotics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Boston Scientific Corporation||$8.71 billion||4.16||$2.31 billion||$0.58||45.54|
|Mazor Robotics||$48.85 million||18.20||-$18.28 million||($0.79)||-46.67|
Boston Scientific Corporation has higher revenue and earnings than Mazor Robotics. Mazor Robotics is trading at a lower price-to-earnings ratio than Boston Scientific Corporation, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
92.1% of Boston Scientific Corporation shares are held by institutional investors. Comparatively, 28.4% of Mazor Robotics shares are held by institutional investors. 0.7% of Boston Scientific Corporation shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This is a breakdown of recent ratings for Boston Scientific Corporation and Mazor Robotics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Boston Scientific Corporation||0||4||13||0||2.76|
Boston Scientific Corporation currently has a consensus price target of $30.39, indicating a potential upside of 15.08%. Mazor Robotics has a consensus price target of $35.00, indicating a potential downside of 5.07%. Given Boston Scientific Corporation’s stronger consensus rating and higher possible upside, analysts plainly believe Boston Scientific Corporation is more favorable than Mazor Robotics.
Risk and Volatility
Boston Scientific Corporation has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Mazor Robotics has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500.
This table compares Boston Scientific Corporation and Mazor Robotics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Boston Scientific Corporation||9.04%||23.62%||9.01%|
Boston Scientific Corporation beats Mazor Robotics on 12 of the 13 factors compared between the two stocks.
Boston Scientific Corporation Company Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.
Mazor Robotics Company Profile
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications. Its Renaissance System and its predecessor are used in a number of spine surgeries, including fusion, correction of spinal deformities, biopsy collection, tumor excision and cement augmentations. Furthermore the Company developed the Renaissance Brain Module, an application of its Renaissance System that provides control over the insertion of surgical instruments during brain surgery.
Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.